Autopsy report · NCT01137136

Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea

“Because of economic issue, we could just enrolled total 150 patients.”

The sponsor’s own words in the registry.

Life of this trial

• Suspended: paused, and may or may not restart.
• 300 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Sponsor

Samsung Medical Center

Sponsor type

University, hospital or other

Conditions

Polymorphism; CYP19; Aromatase Inhibitor

Participants

300 (planned, not actual)

Sites

1

Countries

South Korea

Trials that died the same way

• Duration of Postoperative Antibiotic Prophylaxis in Facial Fractures
  “Limited number of patients” (73% match in meaning)
• Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer
  “The number of patients enrolled was much less than expected” (71% match in meaning)
• Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- Immunotherapy
  “too few patients could be included” (71% match in meaning)
• Proof-of-concept Study of NSAID Hydrogel Patch in Treatment of Acute Pain
  “Due to lack of patients number” (70% match in meaning)
• Epidermal Cells Delivery and Acute Burns
  “Not enough patients included” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.